ExLibris header image
SFX Logo
Title: Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation
Source:

Nature Chemical Biology [1552-4450] Olson, Calla yr:2017


Collapse list of basic services Basic
Sorry, no full text available...
Please use the document delivery service (see below)  
Holding information
Holdings in library search engine ALBERT GO
Document delivery
Request document via Library/Bibliothek GO
Users interested in this article also expressed an interest in the following:
1. Gechijian, L N. "Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands article." Nature Chemical Biology 14.4 (2018): 405-412. Link to SFX for this item
2. Dai, N. "Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents." European journal of medicinal chemistry 146 (2018): 471-482. Link to SFX for this item
3. Winter, Georg E. "BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment." Molecular cell. 67.1: 5-4294967295. Link to SFX for this item
4. Bondeson, Daniel P P. "Catalytic in vivo protein knockdown by small-molecule PROTACs." Nature Chemical Biology 11.8 (2015): 611-7. Link to SFX for this item
5. Vogelstein, B. "Cancer genome landscapes." Science 339.6127 (2013): 1546-1558. Link to SFX for this item
6. Garraway, Levi A. "Lessons from the cancer genome." Cell 153.1 (2013): 17-37. Link to SFX for this item
7. Lai, Ashton C. "Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL." Angewandte Chemie (International ed.) 55.2 (2015): 807-10. Link to Full Text for this item Link to SFX for this item
8. Vogelstein, B. "The Path to Cancer --Three Strikes and You're Out." The New England Journal of Medicine 373.20 (2015): 1895-8. Link to SFX for this item
9. Bradner, James E. "Phthalimide conjugation as a strategy for in vivo target protein degradation." Science 348.6241 (2015): 1376-1381. Link to SFX for this item
10. Bettegowda, C. "Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies." Science translational medicine 6.224 (2014): 224-224. Link to SFX for this item
11. Lawrence, Michael S. "Mutational heterogeneity in cancer and the search for new cancer-associated genes." Nature 499.7457 (2013): 214-218. Link to Full Text for this item Link to SFX for this item
12. SuvÃ, Mario L. "Epigenetic reprogramming in cancer." Science 339.6127 (2013): 1567-1570. Link to SFX for this item
13. "Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update." Journal of medicinal chemistry 63.22: 13228-13257. Link to SFX for this item
14. Andrea, R. "Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence." Cancer management and research 10 (2018): 3083-3099. Link to Full Text for this item Link to SFX for this item
15. Nowak, Radosław P. "Plasticity in binding confers selectivity in ligand-induced protein degradation." Nature Chemical Biology 14.7 (2018): 706-714. Link to SFX for this item
16. Gray, Nathanael S. "Development of Highly Potent and Selective Steroidal Inhibitors and Degraders of CDK8." ACS Medicinal Chemistry Letters 9.6 (2018): 540-545. Link to Full Text for this item Link to SFX for this item
17. Bondeson, Daniel P. "Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead." Cell Chem Biol 25.1: 78-8700000. Link to SFX for this item
18. C, Weir C. "Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth." PLoS One 12.7 (2017). Link to Full Text for this item Link to SFX for this item
19. Melchiore, A. "The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models." Nature 538.7626 (2016): 477-482. Link to Full Text for this item Link to SFX for this item
20. Guenther, M. "Quantitative ChIP-Seq Normalization Reveals Global Modulation of the Epigenome." Cell Reports 9.3 (2014): 1163-1170. Link to SFX for this item
View More...
View Less...
Select All Clear All

Expand list of advanced services Advanced